The recent funding round brings Naveris’ total capital raised to $51 million. The financing will be used to advance the commercialization of Naveris’ blood test tools for the early detection of cancers caused by human papillomavirus, according to the Sept. 19 Naveris news release.
The funding round was led by Gurnet Point Capital, with participation from TechU Ventures and the venture capital arm of the American Cancer Society, BrightEdge.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.